FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W20142860> ?p ?o ?g. }

• W20142860 abstract "A systematic review and economic evaluation of prasugrel compared to clopidogrel after PCIPatients who have undergone percutaneous coronary intervention (PCI) for coronary artery disease usually get a platelet inhibitor (e.g. clopidogrel) for one year after the procedure. Prasugrel is a new platelet inhibitor which is available for patients with acute coronary syndrome (ACS) who undergo PCI in Norway.We aimed to analyze the efficacy and cost-effectiveness of prasugrel compared to clopidogrel for ACS patients who have undergone PCI. This analysis was commissioned by the Norwegian Medicines Agency to support their decision on whether to give reimbursement to prasugrel as well as clopidogrel, which is reimbursed today. We performed a systematic review of randomised controlled trials (RCTs) to estimate the efficacy of prasugrel compared to clopidogrel. Cost-effectiveness analyses were performed in a previously developed Markov model (MOCCA) which simulates clinical events after a PCI is performed. In the model, health and costs are calculated to give the remaining life expectancy and lifetime costs, which again are used to calculate incremental cost-effectiveness of prasugrel compared to clopidogrel.Key messages Prasugrel significantly reduces rates of myocardial infarction and urgent target vessel revascularization compared to clopidogrel in both short term (up to 1 month) and long term (up to 15 months). Quality of the evidence was high and moderate for myocardial infarction and low and moderate for urgent target vessel revascularization. Prasugrel significantly increases rates of bleeding events compared to clopidogrel in both short term and long term data. Quality of the evidence for this outcome was high and low, respectively. The analyses on short and long term effects on mortality revealed no statistically significant differences. Quality of the evidence for this outcome was low and moderate, respectively. Prasugrel is cost-effective compared to clopidogrel for ACS patients who have undergone PCI. Our analyses indicate however that there is uncertainty surrounding the cost-effectiveness result. Uncertainty related to efficacy on mortality and, hence also, cost-effectiveness could be reduced if new randomised controlled trials are performed." @default.
• W20142860 created "2016-06-24" @default.
• W20142860 creator A5046501213 @default.
• W20142860 creator A5058399139 @default.
• W20142860 creator A5067401723 @default.
• W20142860 date "2011-04-01" @default.
• W20142860 modified "2023-09-24" @default.
• W20142860 title "A systematic review and economic evaluation of prasugrel compared to clopidogrel after PCI" @default.
• W20142860 cites W1598602811 @default.
• W20142860 cites W1756335821 @default.
• W20142860 cites W1774610061 @default.
• W20142860 cites W1971428935 @default.
• W20142860 cites W1973239849 @default.
• W20142860 cites W1978913815 @default.
• W20142860 cites W1987702428 @default.
• W20142860 cites W1995512032 @default.
• W20142860 cites W2000037293 @default.
• W20142860 cites W2004487122 @default.
• W20142860 cites W2005726649 @default.
• W20142860 cites W2024352468 @default.
• W20142860 cites W2043258977 @default.
• W20142860 cites W2050211358 @default.
• W20142860 cites W2059875511 @default.
• W20142860 cites W2060192676 @default.
• W20142860 cites W2072269474 @default.
• W20142860 cites W2082902898 @default.
• W20142860 cites W2084155329 @default.
• W20142860 cites W2093709628 @default.
• W20142860 cites W2102393690 @default.
• W20142860 cites W2103598547 @default.
• W20142860 cites W2104863471 @default.
• W20142860 cites W2110108344 @default.
• W20142860 cites W2122962595 @default.
• W20142860 cites W2123328573 @default.
• W20142860 cites W2126756321 @default.
• W20142860 cites W2127324981 @default.
• W20142860 cites W2128324735 @default.
• W20142860 cites W2138058610 @default.
• W20142860 cites W2142075142 @default.
• W20142860 cites W2146453185 @default.
• W20142860 cites W2152823642 @default.
• W20142860 cites W2156506897 @default.
• W20142860 cites W2169387542 @default.
• W20142860 cites W2172024692 @default.
• W20142860 cites W2566929480 @default.
• W20142860 cites W3151002452 @default.
• W20142860 cites W43843458 @default.
• W20142860 cites W906589 @default.
• W20142860 cites W2120616950 @default.
• W20142860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28510407" @default.
• W20142860 hasPublicationYear "2011" @default.
• W20142860 type Work @default.
• W20142860 sameAs 20142860 @default.
• W20142860 citedByCount "0" @default.
• W20142860 crossrefType "journal-article" @default.
• W20142860 hasAuthorship W20142860A5046501213 @default.
• W20142860 hasAuthorship W20142860A5058399139 @default.
• W20142860 hasAuthorship W20142860A5067401723 @default.
• W20142860 hasConcept C126322002 @default.
• W20142860 hasConcept C164705383 @default.
• W20142860 hasConcept C2777028646 @default.
• W20142860 hasConcept C2777849778 @default.
• W20142860 hasConcept C2780400711 @default.
• W20142860 hasConcept C45393284 @default.
• W20142860 hasConcept C500558357 @default.
• W20142860 hasConcept C71924100 @default.
• W20142860 hasConceptScore W20142860C126322002 @default.
• W20142860 hasConceptScore W20142860C164705383 @default.
• W20142860 hasConceptScore W20142860C2777028646 @default.
• W20142860 hasConceptScore W20142860C2777849778 @default.
• W20142860 hasConceptScore W20142860C2780400711 @default.
• W20142860 hasConceptScore W20142860C45393284 @default.
• W20142860 hasConceptScore W20142860C500558357 @default.
• W20142860 hasConceptScore W20142860C71924100 @default.
• W20142860 hasLocation W201428601 @default.
• W20142860 hasOpenAccess W20142860 @default.
• W20142860 hasPrimaryLocation W201428601 @default.
• W20142860 isParatext "false" @default.
• W20142860 isRetracted "false" @default.
• W20142860 magId "20142860" @default.
• W20142860 workType "article" @default.